These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35022206)

  • 1. Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
    Lim SM; Kim CG; Lee JB; Cho BC
    Cancer Discov; 2022 Jan; 12(1):16-19. PubMed ID: 35022206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced
    Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA
    Future Oncol; 2024 May; 20(15):969-980. PubMed ID: 38095056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
    Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA
    Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
    Yu HA; Baik C; Kim DW; Johnson ML; Hayashi H; Nishio M; Yang JC; Su WC; Gold KA; Koczywas M; Smit EF; Steuer CE; Felip E; Murakami H; Kim SW; Su X; Sato S; Fan PD; Fujimura M; Tanaka Y; Patel P; Sternberg DW; Sellami D; Jänne PA
    Ann Oncol; 2024 May; 35(5):437-447. PubMed ID: 38369013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer.
    Lim SM; Kim CG; Cho BC
    Cancer Res; 2022 Jan; 82(1):18-20. PubMed ID: 34983785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
    Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
    Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patritumab deruxtecan shows activity in EGFR-mutant NSCLC.
    Sidaway P
    Nat Rev Clin Oncol; 2023 Dec; 20(12):817. PubMed ID: 37749383
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting HER3 to overcome EGFR TKI resistance in NSCLC.
    Chen Q; Jia G; Zhang X; Ma W
    Front Immunol; 2023; 14():1332057. PubMed ID: 38239350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
    Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
    Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
    Desai S; Kim C; Veytsman I
    Curr Oncol Rep; 2019 Aug; 21(9):84. PubMed ID: 31410582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.
    Pacheco JM
    Cancer Discov; 2021 Jul; 11(7):1617-1619. PubMed ID: 34284994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
    Liu B; Chen D; Chen S; Saber A; Haisma H
    Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
    Lisberg A; Cummings A; Goldman JW; Bornazyan K; Reese N; Wang T; Coluzzi P; Ledezma B; Mendenhall M; Hunt J; Wolf B; Jones B; Madrigal J; Horton J; Spiegel M; Carroll J; Gukasyan J; Williams T; Sauer L; Wells C; Hardy A; Linares P; Lim C; Ma L; Adame C; Garon EB
    J Thorac Oncol; 2018 Aug; 13(8):1138-1145. PubMed ID: 29874546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
    BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
    Linardou H; Dahabreh IJ; Bafaloukos D; Kosmidis P; Murray S
    Nat Rev Clin Oncol; 2009 Jun; 6(6):352-66. PubMed ID: 19483740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.